Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools GIST

GIST

Programs, trials, and reported response and survival for gastrointestinal stromal tumor.

Data as of 11.07.2026

GIST pipeline

Response and survival, trial by trial.

Each card is one trial arm. A bar is a response percent the source states. Progression-free survival, overall survival, and a hazard ratio stay in the units the source used. This page does not subtract one arm from another.

6 arms have a reported figure in this set.

KIT/PDGFRA TKI (type II) 2

multi-kinase TKI 2

Regorafenib

Regorafenib 160 mg, 3 weeks on 1 off

160 mg · ITT

GIST after imatinib and sunitinib

Comparator: placebo

median overall survival: 17.4 months, final OS analysis, 162 events

GRID · NCT01271712

Regorafenib

Placebo

placebo · ITT

GIST after imatinib and sunitinib

median overall survival: 17.4 months, final OS analysis; 88% crossed over

GRID · NCT01271712

switch-control KIT/PDGFRA TKI 2

Ripretinib

Ripretinib 150 mg

150 mg · ITT

GIST after imatinib, sunitinib and regorafenib

Comparator: placebo

median overall survival: 15.1 months, not tested for significance

INVICTUS · NCT03353753

Ripretinib

Placebo

placebo · ITT

GIST after imatinib, sunitinib and regorafenib

median overall survival: 6.6 months, 66% switched to ripretinib

INVICTUS · NCT03353753

A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.